Vascular Biogenics Ltd (VBLT) Expected to Post Earnings of -$0.21 Per Share

Wall Street brokerages predict that Vascular Biogenics Ltd (NASDAQ:VBLT) will report earnings per share (EPS) of ($0.21) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Vascular Biogenics’ earnings, with estimates ranging from ($0.21) to ($0.20). Vascular Biogenics posted earnings per share of ($0.19) during the same quarter last year, which would suggest a negative year-over-year growth rate of 10.5%. The company is scheduled to issue its next earnings results on Monday, May 21st.

According to Zacks, analysts expect that Vascular Biogenics will report full year earnings of ($0.81) per share for the current year, with EPS estimates ranging from ($0.86) to ($0.72). For the next year, analysts expect that the company will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.77) to ($0.74). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Vascular Biogenics.

How to Become a New Pot Stock Millionaire

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Thursday, March 15th. The biopharmaceutical company reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.19. The company had revenue of $13.86 million during the quarter.

A number of equities analysts recently weighed in on VBLT shares. Zacks Investment Research cut Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. HC Wainwright set a $3.00 price target on Vascular Biogenics and gave the stock a “hold” rating in a research note on Thursday, March 22nd. ValuEngine cut Vascular Biogenics from a “sell” rating to a “strong sell” rating in a research note on Friday, March 9th. Piper Jaffray cut Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research note on Thursday, March 8th. Finally, Chardan Capital cut Vascular Biogenics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $3.00 in a research note on Thursday, March 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $3.19.

Institutional investors and hedge funds have recently modified their holdings of the stock. IFP Advisors Inc increased its stake in Vascular Biogenics by 339.7% in the 4th quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 15,117 shares in the last quarter. Alps Advisors Inc. purchased a new position in Vascular Biogenics during the 4th quarter valued at about $234,000. ARK Investment Management LLC purchased a new position in Vascular Biogenics during the 4th quarter valued at about $302,000. Finally, Raymond James & Associates grew its stake in Vascular Biogenics by 71.5% during the 4th quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock valued at $394,000 after acquiring an additional 23,124 shares in the last quarter. 5.58% of the stock is currently owned by hedge funds and other institutional investors.

VBLT traded up $0.15 during trading on Tuesday, reaching $2.25. The company had a trading volume of 175,932 shares, compared to its average volume of 389,625. The stock has a market capitalization of $62.04, a P/E ratio of -6.08 and a beta of -1.67. Vascular Biogenics has a 12-month low of $2.01 and a 12-month high of $9.05.

ILLEGAL ACTIVITY WARNING: This report was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://weekherald.com/2018/04/17/vascular-biogenics-ltd-vblt-expected-to-post-earnings-of-0-21-per-share.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply